Soft Tissue Sarcoma with Lung Metastases Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight

The market dynamics for Soft Tissue Sarcoma with Lung Metastases is witnessing steady growth driven by the rising Disease Incidence and Improved Diagnostic Capabilities, Increasing Demand for Effective Systemic Anticancer Therapies, and Growing Preference for Personalized and Multidisciplinary Treatment Approaches. Additionally, the launch of emerging therapies such as Annamycin (Moleculin Biotech), IP-001 (Immunophotonics), and others will further fuel the market.
DelveInsight's Soft Tissue Sarcoma with Lung Metastases Market Insights, Epidemiology, and Market Forecast 2036." This comprehensive report provides an in-depth understanding of Soft Tissue Sarcoma with Lung Metastases, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

Key Takeaways from the Soft Tissue Sarcoma with Lung Metastases Market

*
The market size for Soft Tissue Sarcoma with Lung Metastases in the leading markets is expected to grow significantly by 2036.

*
The United States accounted for the highest Soft Tissue Sarcoma with Lung Metastases treatment market size in 7MM in 2025, in comparison to the other major markets, i.e., EU4 countries, the United Kingdom, and Japan.

*
Based on secondary research, STS represents a meaningful oncologic burden, with approximately 14,000 new cases diagnosed annually in the US. Notably, up to 50% of these patients eventually develop lung metastases, highlighting the substantial progression risk and the clinical impact of STS-LM.

*
Leading soft tissue sarcoma with lung metastases companies, such as Moleculin, Immunophotonics, Philogen, Iovance Biotherapeutics, Chipscreen, Lyvgen, and others, are developing new soft tissue sarcoma with lung metastases treatment drugs that can be available in the soft tissue sarcoma with lung metastases market in the coming years.

*
The promising soft tissue sarcoma with lung metastases therapies in clinical trials include Annamycin, IP-001, Fibromun, Lifileucel, Chiauranib, LVGN6051, and others.

Keen to know more about the market? Request our sample page at https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Key Factors Driving the Soft Tissue Sarcoma with Lung Metastases Market

Rising Disease Incidence and Improved Diagnostic Capabilities: Improved imaging technologies, increased disease awareness, and enhanced longitudinal monitoring are helping identify more patients with pulmonary metastatic soft tissue sarcoma. Earlier diagnosis and better recognition of advanced metastatic disease are contributing to treatment demand.

Increasing Demand for Effective Pharmacological Therapies: Pharmacological treatment of STS-LM primarily involves systemic anticancer therapies tailored to disease extent, histology, and prior therapy. Targeted cellular therapies such as TECELRA (afamitresgene autoleucel) are also emerging as precision treatment options for eligible patients.

Growing Preference for Personalized and Multidisciplinary Treatment Approaches: Non-pharmacological treatment approaches such as pulmonary metastasectomy, stereotactic body radiotherapy, and localized ablative techniques are increasingly utilized. Multidisciplinary treatment planning is gaining traction to optimize outcomes in advanced disease settings.

Soft Tissue Sarcoma with Lung Metastases Competitive Landscape

*
TECELRA (afamitresgene autoleucel) (USWM): Approved genetically modified autologous T-cell therapy for adults with unresectable or metastatic synovial sarcoma with specific HLA-A*02 subtypes whose tumors express MAGE-A4 antigen.

*
Annamycin (Moleculin Biotech): Investigational next-generation anthracycline designed to overcome multidrug resistance and reduce cardiotoxicity. Currently in Phase I/II development.

*
IP-001 (Immunophotonics): Investigational intratumoral immunotherapy employing a photothermal mechanism to induce localized tumor cell death and stimulate systemic anti-tumor immune responses. Currently in Phase I/II development.

Discover more about therapies set to grab major Soft Tissue Sarcoma with Lung Metastases market share @ Soft Tissue Sarcoma with Lung Metastases Treatment Landscape [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Recent Developments in the Soft Tissue Sarcoma with Lung Metastases Market

*
In June 2025, Moleculin Biotech reported promising efficacy results for Annamycin from its Phase Ib/II clinical trial in patients with STS-LM.

*
In August 2024, the US FDA granted accelerated approval to TECELRA (afamitresgene autoleucel) for adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and whose tumors express MAGE-A4 in HLA-A*02 positive patients.

*
In September 2023, Immunophotonics reported that the first patient was dosed in its multinational clinical trial in France for IP-001.

What is Soft Tissue Sarcoma with Lung Metastases?

Soft Tissue Sarcoma with Lung Metastases represents an advanced stage of soft tissue sarcoma in which malignant tumors of mesenchymal origin have spread to the lungs, reflecting aggressive disease biology, significant tumor burden, and limited therapeutic options. Diagnosis is based on imaging, most commonly chest CT, to identify pulmonary metastases, with histopathologic confirmation when required to verify metastatic sarcoma.

Soft Tissue Sarcoma with Lung Metastases Epidemiology Segmentation

The Soft Tissue Sarcoma with Lung Metastases epidemiology section provides insights into the historical and current patient pool and forecasted trends for the leading markets. The Soft Tissue Sarcoma with Lung Metastases market report proffers epidemiological analysis for the study period 2022-2036 in the leading markets, segmented into:

*
Total Incident Cases of Soft Tissue Sarcoma with Lung Metastases

*
Total Incident Cases of Soft Tissue Sarcoma

*
Gender-specific Incident Cases of Soft Tissue Sarcoma with Lung Metastases

*
Country-wise Incident Cases of Soft Tissue Sarcoma with Lung Metastases

Scope of the Soft Tissue Sarcoma with Lung Metastases Market Report

*
Therapeutic Assessment: Soft Tissue Sarcoma with Lung Metastases current marketed and emerging therapies

*
Soft Tissue Sarcoma with Lung Metastases Market Dynamics: Key Market Forecast Assumptions of Emerging Soft Tissue Sarcoma with Lung Metastases Drugs and Market Outlook

*
Key Companies: Moleculin, Immunophotonics, Philogen, Iovance Biotherapeutics, Chipscreen, Lyvgen

*
Key Therapies: Annamycin, IP-001, Fibromun, Lifileucel, Chiauranib, LVGN6051, TECELRA

*
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies

*
Unmet Needs, KOL's views, Analyst's views, Soft Tissue Sarcoma with Lung Metastases Market Access and Reimbursement

To know more about Soft Tissue Sarcoma with Lung Metastases companies working in the treatment market, visit @ Soft Tissue Sarcoma with Lung Metastases Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=kspr]

Table of Contents

*
Soft Tissue Sarcoma with Lung Metastases Market Report Introduction

*
Executive Summary for Soft Tissue Sarcoma with Lung Metastases

*
SWOT Analysis of Soft Tissue Sarcoma with Lung Metastases

*
Soft Tissue Sarcoma with Lung Metastases Patient Share (%) Overview at a Glance

*
Soft Tissue Sarcoma with Lung Metastases Market Overview at a Glance

*
Soft Tissue Sarcoma with Lung Metastases Background and Overview

*
Soft Tissue Sarcoma with Lung Metastases Epidemiology and Patient Population

*
Country-Specific Patient Population of Soft Tissue Sarcoma with Lung Metastases

*
Soft Tissue Sarcoma with Lung Metastases Current Treatment and Medical Practices

*
Soft Tissue Sarcoma with Lung Metastases Unmet Needs

*
Soft Tissue Sarcoma with Lung Metastases Emerging Therapies

*
Soft Tissue Sarcoma with Lung Metastases Market Outlook

*
Country-Wise Soft Tissue Sarcoma with Lung Metastases Market Analysis (2022-2036)

*
Soft Tissue Sarcoma with Lung Metastases Market Access and Reimbursement of Therapies

*
Soft Tissue Sarcoma with Lung Metastases Market Drivers

*
Soft Tissue Sarcoma with Lung Metastases Market Barriers

*
Soft Tissue Sarcoma with Lung Metastases Appendix

*
Soft Tissue Sarcoma with Lung Metastases Report Methodology

*
DelveInsight Capabilities

*
Disclaimer

*
About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=soft-tissue-sarcoma-with-lung-metastases-market-is-projected-to-boom-by-2036-owing-to-the-launch-of-novel-therapies-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.